Rational Design and Synthesis of Novel Dimeric Diketoacid-Containing Inhibitors of HIV-1 Integrase: Implication for Binding to Two Metal Ions on the Active Site of Integrase

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2561-2573

  Long, Ya Qiu ^a   Jiang, Xiao Hua ^a   Dayam, Raveendra ^d   Sanchez, Tino ^d   Shoemaker, Robert ^c   Sei, Shizuko ^b   Neamati, Nouri ^d  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; BETA DIKETOACID DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; DIMER; INTEGRASE; INTEGRASE INHIBITOR; MAGNESIUM ION; METAL CHELATE; METAL ION; OLIGONUCLEOTIDE; OXOACID; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOPATHOGENIC EFFECT; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN;

BINDING SITES; CELL LINE; CHELATING AGENTS; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; DRUG DESIGN; HIV INTEGRASE; HIV-1; HUMANS; KETO ACIDS; MAGNESIUM; MODELS, MOLECULAR; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 2342561153     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030559k     Document Type: Article

References (49)

1. Brown, P. O. Integration; Cold Spring Harbor Press: Cold Spring Harbor, 1999.
2. Asante-Appiah, E.; Skalka, A. M. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 1999, 52, 351-369.
3. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discovery 2002, 1, 13-25.
4. Richman, D. D. HIV chemotherapy. Nature 2001, 410, 995-1001.
5. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: a ten-year saga. Expert Opin. Ther. Pat. 2002, 12, 709-724.
6. Neamati, N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opin. Invest. Drugs 2001, 10, 281-296.
7. Dayam, R.; Neamati, N. Small-Molecule HIV-1 Integrase Inhibitors: the 2001-2002 Update. Curr. Pharm. Des. 2003, 9, 1789-1802.
8. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
9. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. in Vitro Activity of a New HIV-1 Integrase Inhibitor in Clinical Development. 9th Conference on retroviruses and opportunistic infections: Seattle, 2002.
10. Billich, A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 2003, 4, 206-209.
11. Este, J. A.; Cabrera, C.; Schols, D.; Cherepanov, P.; Gutierrez, A.; Witvrouw, M.; Pannecouque, C.; Debyser, Z.; Rando, R. F.; Clotet, B.; Desmyter, J.; De Clercq, E. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. 1998, 53, 340-345.
12. Pluymers, W.; Neamati, N.; Pannecouque, C.; Fikkert, V.; Marchand, C.; Burke, T. R., Jr.; Pommier, Y.; Schols, D.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetraacetyl eaters. Mol. Pharmacol. 2000, 58, 641-648.
13. Espeseth, A. S.; Felock, P.; Wolfe, A.; Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, M.; Melamed, J. Y.; Young, S.; Hamill, T.; Cole, J. L.; Hazuda, D. J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U S A 2000, 97, 11244-11249.
14. Zhuang, L.; Wai, J. S.; Embrey, M. W.; Fisher, T. E.; Egbertson, M. S.; Payne, L. S.; Guare, J. P., Jr.; Vacca, J. P.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Witmer, M. V.; Moyer, G.; Schleif, W. A.; Gabryelski, L. J.; Leonard, Y. M.; Lynch, J. J., Jr.; Michelson, S. R.; Young, S. D. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 2003, 46, 453-456.
15. Pais, G. C.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E. S.; Pathak, V. K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T. R., Jr. Structure Activity of 3-Aryl-1,3-diketo-Containing Compounds as HIV-1 Integrase Inhibitors. J. Med. Chem. 2002, 45, 3184-3194.
16. Marchand, C.; Zhang, X.; Pais, G. C.; Cowansage, K.; Neamati, N.; Burke, T. R., Jr.; Pommier, Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J. Biol. Chem. 2002, 277, 12596-12603.
17. Pluymers, W.; Pais, G.; Van Maele, B.; Pannecouque, C.; Fikkert, V.; Burke, T. R., Jr.; De Clercq, E.; Witvrouw, M.; Neamati, N.; Debyser, Z. Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives. Antimicrob Agents Chemother. 2002, 46, 3292-3297.
18. Pais, G. C. G.; Burke, T. R. Novel aryl diketo-containing inhibitors of HIV-1 integrase. Drugs Future 2002, 27, 1101-1111.
19. Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W. ; Tran, L. O.; Melamed, J. Y.; Langford, H. M.; Guare, J. P., Jr.; Zhuang, L.; Grey, V. E.; Vacca, J. P.; Holloway, M. K.; Naylor-Olsen, A. M.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Schleif, W. A.; Gabryelski, L. J.; Young, S. D. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem. 2000, 43, 4923-4926.
20. Esposito, D.; Craigie, R. HIV integrase structure and function. Adv. Virus Res. 1999, 52, 319-333.
21. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad Sci. U S A 1999, 96, 13040-13043.
22. Sherman, P. A.; Fyfe, J. A. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proc. Natl. Acad. Sci. U S A 1990, 87, 5119-5123.
23. Jones, K. S.; Coleman, J.; Merkel, G. W.; Laue, T. M.; Skalka, A. M. Retroviral integrase functions as a multimer and can turn over catalytically. J. Biol. Chem. 1992, 267, 16037-16040.
24. Vincent, K. A.; Ellison, V.; Chow, S. A.; Brown, P. O. Characterization of human immunodeficiency virus type 1 integrase expressed in Escherichia coli and analysis of variants with amino-terminal mutations. J. Virol. 1996, 67, 425-437.
25. Jenkins, T. M.; Engelman, A.; Ghirlando, R.; Craigie, R. A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J. Biol. Chem. 1996, 271, 7712-7718.
26. Heuer, T. S.; Brown, P. O. Photocross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry 1998, 37, 6667-6678.
27. Wang, J. Y.; Ling, H.; Yang, W.; Craigie, R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 2001, 20, 7333-7343.
28. De Luca, L.; Pedretti, A.; Vistoli, G.; Barreca, M. L.; Villa, L.; Monforte, P.; Chimirri, A. Analysis of the full-length integrase-DNA complex by a modified approach for DNA docking. Biochem. Biophys. Res. Commun. 2003, 310, 1083-1088.
29. Podtelezhnikov, A. A.; Gao, K.; Bushman, F. D.; McCammon, J. A. Modeling HIV-1 integrase complexes based on their hydrodynamic properties. Biopolymers 2003, 68, 110-120.
30. Cowan, J. A. The Biological Chemistry of Magnesium; VCH: 1995; pp 1-23.
31. Neamati, N.; Lin, Z.; Karki, R. G.; Orr, A.; Cowansage, K.; Strumberg, D.; Pais, G. C.; Voigt, J. H.; Nicklaus, M. C.; Winslow, H. E.; Zhao, H.; Turpin, J. A.; Yi, J.; Skalka, A. M.; Burke, T. R., Jr.; Pommier, Y. Metal-dependent inhibition of HIV-1 integrase. J. Med. Chem. 2002, 45, 5661-5670.
32. Steitz, T. A. DNA polymerases: structural diversity and common mechanisms. J. Biol. Chem. 1999, 274, 17395-17398.
33. Steitz, T. A. A mechanism for all polymerases. Nature 1998, 391, 231-232.
34. Lins, R. D.; Adesokan, A.; Soares, T. A.; Briggs, J. M. Investigations on human immunodeficiency virus type 1 integrase/DNA binding interactions via molecular dynamics and electrostatics calculations. Pharmacol. Ther. 2000, 85, 123-131.
35. Bujacz, G.; Alexandratos, J.; Qing, Z. L.; Clement-Mella, C.; Wlodawer, A. The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. FEBS Lett. 1996, 398, 175-178.
36. Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Engelman, A.; Craigie, R.; Davies, D. R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266, 1981-1986.
37. Chen, J. C.; Krucinski, J.; Miercke, L. J.; Finer-Moore, J. S.; Tang, A. H.; Leavitt, A. D.; Stroud, R. M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8233-8238.
38. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9150-9154.
39. Greenwald, J.; Le, V.; Butler, S. L.; Bushman, F. D.; Choe, S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 1999, 38, 8892-8898.
40. Maignan, S.; Guilloteau, J. P.; Zhou-Liu, Q.; Clement-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282, 359-368.
41. Smonou, I. One step reduction of diaryl ketones to hydrocarbons by etherated boron trifluoride-triethylsilane system. Synth. Commun. 1994, 24, 1999-2002.
42. Nahm, S.; Weinreb, S. M. N-Methoxy-N-methylamides as effective acylating agents. Tetrahedron Lett. 1981, 22, 3815-3818.
43. Bachmann, W. E.; Cole, W.; Wilds, A. L. The total synthesis of the sex hormone Equilenin and its stereoisomers. J. Am. Chem. Soc. 1940, 62, 824-839.
44. Jiang, X. H.; Song, L. D.; Long, Y. Q. Highly Efficient Preparation of Aryl beta-Diketo Acids with tert-Butyl Methyl Oxalate. J. Org. Chem. 2003, 68, 7555-7558.
45. Sotriffer, C. A.; Ni, H.; McCammon, A. J. HIV-1 Integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J. Am. Chem. Soc 2000, 122, 6136-6137.
46. Barreca, M. L.; Lee, K. W.; Chimirri, A.; Briggs, J. M. Molecular Dynamics Studies of the Wild-Type and Double Mutant HIV-1 Integrase Complexed with the 5CITEP Inhibitor: Mechanism for Inhibition and Drug Resistance. Biophys. J. 2003, 84, 1450-1463.
47. Weislow, O. W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
48. Smellie, A.; Teig, S. L.; Towbin, P. Poling - Promoting Conformational Variation. J. Comput. Chem. 1995, 16, 171-187.
49. CCDC, C. C. E., UK GOLD; 1.2 ed.